Table 2.
Disease burden at baseline (all treatment groups combined)
| Characteristic, mean (SD) | LEI > 0 (N = 403)a |
LDI-B > 0 (N = 155)a |
Integrated analysis set (N = 679) |
|---|---|---|---|
| Pt assessment of joint pain, mm |
n = 392 63.7 (19.7) |
n = 151 66.9 (20.7) |
n = 665 61.4 (21.1) |
| PtGA of disease activity, mm |
n = 392 64.6 (20.9) |
n = 151 68.6 (21.1) |
n = 665 63.9 (20.8) |
| HAQ-DI total score |
n = 391 1.3 (0.6) |
n = 151 1.3 (0.7) |
n = 664 1.2 (0.6) |
| EQ-5D 5L |
n = 389 0.6 (0.2) |
n = 151 0.5 (0.2) |
n = 661 0.6 (0.2) |
| EQ-5D VAS |
n = 389 52.5 (19.8) |
n = 151 52.6 (21.9) |
n = 661 54.1 (20.9) |
Abbreviations: EQ-5D 5L EuroQoL-5 Dimensions 5 level, HAQ-DI Health Assessment Questionnaire-Disability Index, N number of patients in analysis population, n number of patients with non-missing data, Pt patient, PtGA patient global assessment, VAS visual analogue scale
aBaseline enthesitis defined as a baseline LEI score > 0 and baseline dactylitis defined as a baseline LDI-B score > 0